International Clinical Trial: Dupilumab for Moderate-to-Severe Eczema: Efficacy and Safety in Real-World Use

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132823) titled 'Dupilumab for Moderate-to-Severe Eczema: Efficacy and Safety in Real-World Use' on Sept. 18.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: The Second Affiliated Hospital of Xi'an Jiaotong University

Condition: Moderate-to-severe atopic dermatitis (AD)

Recruitment Status: Not Recruiting

Phase: N/A

Date of First Enrollment: 2025-11-30

Target Sample Size: Dupilumab treatment group:720;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=304582

Published by HT Digital Content Services with permission from Health Daily Digest....